Beneficial effects of torasemide on systolic wall stress and sympathetic nervous activity in asymptomatic or mildly symptomatic patients with heart failure: Comparison with azosemide

Journal of Cardiovascular Pharmacology

Volumn 53, Issue 6, 2009, Pages 468-473

  Harada, Ken ^a   Izawa, Hideo ^b   Nishizawa, Takao ^a   Hirashiki, Akihiro ^a   Murase, Yosuke ^a   Kobayashi, Masakazu ^a   Isobe, Satoshi ^a   Xian, Wu Cheng ^a   Noda, Akiko ^c   Nagata, Kohzo ^c   Yokota, Mitsuhiro ^d   Murohara, Toyoaki ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b FUJITA HEALTH UNIVERSITY   (Japan)

^c NAGOYA UNIVERSITY   (Japan)

^d Aichi Gakuin School of Dentistry   (Japan)

Author keywords

Aldosterone; Heart failure; LV systolic wall stress; Norepinephrine; Sympathetic nervous system; Torasemide

Indexed keywords

ALDOSTERONE; AZOSEMIDE; FUROSEMIDE; NORADRENALIN; TORASEMIDE;

ADRENERGIC ACTIVITY; ADULT; ALDOSTERONE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; CONTRACTION STRESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; FEMALE; HEART FAILURE; HEART HEMODYNAMICS; HUMAN; MALE; NORADRENALIN BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ALDOSTERONE; ALDOSTERONE ANTAGONISTS; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; NOREPINEPHRINE; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS; SULFANILAMIDES; SULFONAMIDES; SYMPATHETIC NERVOUS SYSTEM; SYSTOLE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 68249124923     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181a717f7     Document Type: Article

References (30)

1. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005;112: e154-e235.
2. Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26:1115-1140.
3. Lenzen MJ, Scholte op Reimer WJ, Boersma E, et al. Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey. Eur Heart J. 2004;25:1214-1220.
4. Yoshida J, Yamamoto K, Mano T, et al. Different effects of long- and short-acting loop diuretics on survival rate in Dahl high-salt heart failure model rats. Cardiovasc Res. 2005;68:118-127. (Pubitemid 41253562)
5. Domanski M, Norman J, Pitt B, et al. Diuretic use, progressive heart failure, and death in patients in the studies of left ventricular dysfunction (SOLVD). J Am Coll Cardiol. 2003;42:705-708. (Pubitemid 37000189)
6. Domanski M, Tian X, Haigney M, et al. Diuretic use, progressive heart failure, and death in patients in the DIG study. J Card Fail. 2006;12: 327-332. (Pubitemid 43817590)
7. Tsutsui T, Tsutamoto T, Maeda K, et al. Comparison of neurohumoral effects of short-acting and long-acting loop diuretics in patients with chronic congestive heart failure. J Cardiovasc Pharmacol. 2001;38(Suppl 1): S81-S85. (Pubitemid 33104689)
8. Brater DC. Diuretic therapy. N Engl J Med. 1998;339:387-395.
9. Murray MD, Deer MM, Ferguson JA, et al. Open-label randomized trial of torasemide compared with furosemide therapy for patients with heart failure. Am J Med. 2001;111:513-520.
10. Cosin J, Diez J. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail. 2002;4:507-513. (Pubitemid 36564972)
11. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341: 709-717.
12. Uchida T, Yamanaga K, Nishikawa M, et al. Anti-aldosteronergic effect of torasemide. Eur J Pharmacol. 1991;205:145-150.
13. Goodfriend TL, Ball DL, Oelkers W, et al. Torasemide inhibits aldosterone secretion in vitro. Life Sci. 1998;63:PL45-PL50. (Pubitemid 28305573)
14. Francis GS. The relationship of the sympathetic nervous system and the renin-angiotensin system in congestive heart failure. Am Heart J. 1989; 118:642-648. (Pubitemid 19222071)
15. Wang W. Chronic administration of aldosterone depresses baroreceptor reflex function in the dog. Hypertension. 1994;24:571-575. (Pubitemid 24337826)
16. MacFadyen RJ, Barr CS, Struthers AD. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res. 1997;35:30-34.
17. Grossman W, Jones D, McLaurin LP. Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest. 1975;56:56-64.
18. Reichek N, Wilson J, St. John Sutton M, et al. Noninvasive determination of left ventricular end-systolic stress: validation of the method and initial application. Circulation. 1982;65:99-108. (Pubitemid 12250896)
19. Levine TB, Francis GS, Goldsmith SR, et al. Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure. Am J Cardiol. 1982;49:1659-1666.
20. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation. 1991;83: 1849-1865.
21. Begona L, Arantxa G, Javier B, et al. Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure. J Am Coll Cardiol. 2007;50:859-867.
22. Yamamoto K, Nishimura RA, Chaliki HP, et al. Determination of left ventricular filling pressure by Doppler echocardiography in patients with coronary artery disease: critical role of left ventricular systolic function. J Am Coll Cardiol. 1997;30:1819-1826. (Pubitemid 27521268)
23. Lake CR, Ziegler MG, Kopin IJ. Use of plasma norepinephrine for evaluation of sympathetic neuronal function in man. Life Sci. 1976;18: 1315-1325.
24. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311:819-823. (Pubitemid 14035089)
25. Kaye DM, Lefkovits J, Jennings GL, et al. Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol. 1995;26:1257-1263.
26. Brunner-La Rocca HP, Esler MD, Jennings GL, et al. Effect of cardiac sympathetic nervous activity on mode of death in congestive heart failure. Eur Heart J. 2001;22:1136-1143. (Pubitemid 32666655)
27. Henderson EB, Kahn JK, Corbett JR, et al. Abnormal I-123 metaiodobenzylguanidine myocardial washout and distribution may reflect myocardial adrenergic derangement in patients with congestive cardiomyopathy. Circulation. 1988;78(pt 1):1192-1199.
28. Kasama S, Toyama T, Hatori T, et al. Effects of torasemide on cardiac sympathetic nerve activity and left ventricular remodelling in patients with congestive heart failure. Heart. 2006;92:1434-1440. (Pubitemid 44578836)
29. Mizuno Y, Yoshimura M, Yasue H, et al. Aldosterone production is activated in failing ventricle in humans. Circulation. 2001;103:72-77. (Pubitemid 32050438)
30. Guder G, Bauersachs J, Frantz S, et al. Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation. 2007;115:1754-1761. (Pubitemid 46648612)